Related by context. All words. (Click for frequent words.) 69 IV NSCLC 67 stage IIIB 65 unresectable 65 unresectable stage 64 metastatic renal cell carcinoma 64 IV melanoma 63 IV metastatic melanoma 63 stage IIIA 61 patients evaluable 61 recurrent glioblastoma multiforme 61 evaluable 61 leukemia AML 60 metastatic GIST 60 stage IIIb 60 leukemia CLL 60 RECIST criteria 60 metastatic pancreatic cancer 60 medullary thyroid cancer 60 evaluable patients 60 metastatic RCC 60 HBeAg positive patients 59 chronic plaque psoriasis 59 neoadjuvant chemotherapy 59 recurrent NSCLC 59 mRCC 59 stage IIIB IV 59 gastrointestinal stromal tumor GIST 59 chlorambucil 58 metastatic NSCLC 58 vandetanib 58 recurrent glioblastoma 58 heavily pretreated 58 dacarbazine DTIC 58 cell lymphoma CTCL 58 advanced NSCLC 58 cytogenetic responses 57 unresectable locally advanced 57 Hodgkin lymphoma NHL 57 metastatic malignant melanoma 57 fallopian tube carcinoma 57 follicular lymphoma 57 lupus nephritis 57 histologically confirmed 57 resectable 57 NSCLC 57 hepatic metastases 57 partial remissions 57 FOLFOX 57 relapsed multiple myeloma 57 chemo radiotherapy 57 relapsed refractory multiple myeloma 57 prior chemotherapy regimens 57 tumor shrinkage 56 refractory NSCLC 56 metastatic HRPC 56 relapsing multiple sclerosis 56 FOLFOX4 56 severe oral mucositis 56 free survival PFS 56 autoantibody positive 56 rituximab refractory 56 ribavirin RBV 56 stage IIIb IV 56 T#I mutation 56 platinum refractory 56 pancreatic NET 56 cholangiocarcinoma 56 splenectomized 56 lymphoma CTCL 56 dasatinib Sprycel ® 56 relapsing MS 56 chemoradiotherapy 56 RECIST 56 primary peritoneal 56 HBeAg positive 56 Fludara 56 relapsed CLL 56 multiple myeloma MM 56 CTCL 56 relapsed SCLC 56 leukemia ALL 56 cisplatin chemotherapy 56 dacarbazine 56 mCRC patients 56 cervical carcinoma 55 placebo dexamethasone 55 Tarceva erlotinib 55 cytogenetic response 55 metastatic renal cell 55 follicular NHL 55 castration resistant prostate cancer 55 metastatic kidney 55 myelodysplastic syndrome MDS 55 basal cell carcinoma BCC 55 pegylated interferon alfa 2b 55 metastatic gastric 55 systemic lupus erythematosus SLE 55 leukemia APL 55 remission induction 55 relapsing remitting 55 precancerous cervical lesions 55 sunitinib 55 Doxil ® 55 chemoradiation 55 PsA 55 non metastatic osteosarcoma 55 renal cell carcinoma 55 IIIA NSCLC 55 locoregional 55 systemic ALCL 55 HBeAg negative patients 55 metastatic prostate cancer 55 IBS C 55 tyrosine kinase inhibitors TKIs 55 metastatic malignant 55 liver metastases 55 Acute Myeloid Leukemia AML 55 situ CIS 55 hepatocellular carcinoma HCC 55 glufosfamide 55 docetaxel chemotherapy 55 relapsing remitting multiple sclerosis 55 Response Evaluation Criteria 54 underwent resection 54 PegIFN RBV 54 immune thrombocytopenic purpura ITP 54 complete remissions 54 IV malignant melanoma 54 non splenectomized 54 metastatic disease 54 epithelial ovarian cancer 54 biliary tract cancer 54 metastatic squamous cell carcinoma 54 cetuximab 54 lymphocytosis 54 corticosteroids immunoglobulins 54 complete cytogenetic 54 achieved ACR# 54 neoadjuvant therapy 54 antibody MAb 54 epithelial ovarian 54 pegylated interferon alpha 54 HER2 positive metastatic breast 54 Glioblastoma Multiforme 54 heterozygous FH 54 refractory CLL 54 achieved sustained virologic 54 ACTEMRA TM 54 myelofibrosis 54 heavily pretreated patients 54 ovarian carcinoma 54 tumor recurrence 54 NYHA Class II 54 idiopathic pulmonary fibrosis IPF 54 tumor lysis syndrome 54 dosing cohort 54 eosinophilic asthma 54 pancreatic adenocarcinoma 54 FOLFIRI 54 tumors GIST 54 huN# DM1 54 refractory multiple myeloma 54 severe neutropenia 54 peginterferon 54 Pegasys ® 54 adalimumab 54 GISTs 54 curative resection 54 hepatorenal syndrome 54 achieve sustained virologic 54 dose escalation phase 54 refractory gout 54 HBeAg negative 54 EGFR TKI 54 interferon therapy 54 transitional cell carcinoma 54 PREZISTA r 54 plus dexamethasone 54 bortezomib refractory 54 metastatic bladder 54 gastrointestinal stromal tumors GIST 54 docetaxel prednisone 54 anterior uveitis 54 CHOP chemotherapy 54 CLL SLL 54 HBeAg negative chronic hepatitis 54 GvHD 53 locoregional disease 53 imatinib therapy 53 Metastatic breast cancer 53 non squamous NSCLC 53 relapsed refractory 53 distant metastases 53 gemcitabine carboplatin 53 chronic lymphocytic leukemia CLL 53 HCV genotype 53 8mg/kg 53 splenectomized patients 53 Acute Myelogenous Leukemia AML 53 Metastatic Colorectal Cancer 53 metastatic melanoma 53 CIMZIA TM 53 Follicular Lymphoma 53 TACE 53 receiving golimumab 53 pancreatic neuroendocrine tumors 53 hypercalcemia 53 imatinib resistant 53 carcinoid cancer 53 Ph + ALL 53 recurrent GBM 53 acute myelogenous leukemia AML 53 chronic myeloid leukemia CML 53 relapsing remitting MS 53 gemcitabine chemotherapy 53 TNF antagonist 53 plus gemcitabine 53 EGFR mutation positive 53 estramustine 53 Solid Tumors criteria 53 hepatitis C genotype 53 receptor tyrosine kinase inhibitor 53 cutaneous T 53 thymoma 53 Acute Myeloid Leukaemia AML 53 cytologically confirmed 53 cutaneous T cell 53 EGFR inhibitors 53 chemoradiation therapy 53 interferon ribavirin 53 evaluable subjects 53 systemic lupus erythematosus 53 carboplatin paclitaxel 53 interferon alfa 2a 53 corticosteroid therapy 53 progressive PsA 53 proliferative diabetic retinopathy 53 macroalbuminuria 53 neuroendocrine cancers 53 plaque psoriasis 53 pT3 53 chronic angina 53 diabetic nephropathy 53 HER2 positive breast cancer 53 idiopathic thrombocytopenic purpura ITP 53 ALND 53 castrate resistant prostate cancer 53 advanced hepatocellular carcinoma 53 anaplastic astrocytoma 53 malignant pleural mesothelioma 53 rituximab 53 Relapsed Refractory 53 Hepatocellular Carcinoma HCC 53 nab paclitaxel 53 gefitinib 53 symptomatic BPH 53 prostate cancer CRPC 53 Carcinoma 53 mg kg dose 53 ATTR PN 53 metastatic SCCHN 53 CCyR 53 Myelofibrosis 53 ischemic cardiomyopathy 53 dasatinib 53 gastrointestinal stromal tumors 53 Rheumatoid Arthritis RA 53 indolent NHL 53 MCyR 53 Cutaneous T 53 chronic GVHD 53 refractory CTCL 53 IMGN# 53 erlotinib Tarceva ® 53 refractory ovarian cancer 53 unresectable Stage III 53 squamous cell carcinoma SCC 53 mycophenolate mofetil 53 KRAS wild 52 DLBCL 52 hepatocellular carcinoma 52 mg BID 52 completely resected 52 bendamustine 52 familial amyloidotic polyneuropathy FAP 52 gefitinib Iressa 52 follicular lymphomas 52 colorectal cancer liver metastases 52 Myelodysplastic Syndrome MDS 52 receiving highly emetogenic 52 APTIVUS r 52 androgen independent 52 preoperative chemotherapy 52 peginterferon alfa 2a 52 mg/m2 dose 52 Retinitis Pigmentosa RP 52 CMV disease 52 fludarabine 52 cutaneous squamous cell carcinoma 52 adjuvant chemotherapy 52 CR CRu 52 cabazitaxel 52 ErbB2 positive 52 Aflibercept 52 CTAP# Capsules 52 metastatic 52 cilengitide 52 pheochromocytoma 52 vinorelbine 52 prostate adenocarcinoma 52 squamous cell carcinoma 52 methotrexate MTX 52 purpura ITP 52 renal tumors 52 KRAS mutations occur 52 Toxicities 52 RECIST Response Evaluation Criteria 52 Torisel 52 metastatic CRC 52 relapsed Hodgkin lymphoma 52 KRAS mutant tumors 52 relapsing remitting MS RRMS 52 grade cervical intraepithelial 52 CIMZIA ™ 52 small lymphocytic lymphoma 52 Castration Resistant Prostate Cancer 52 rindopepimut 52 ADPKD 52 Sezary syndrome 52 temsirolimus 52 Bezielle 52 pT2 52 fallopian tube cancers 52 azacitidine 52 amrubicin 52 acute myeloid 52 #mg/m# [001] 52 mCRC acneform rash 52 mildly symptomatic 52 esophageal candidiasis 52 breast carcinoma 52 chronic ITP patients 52 cancer mCRC 52 Tamibarotene 52 5-FU/LV 52 fluoropyrimidine 52 recurrent metastatic 52 gastrointestinal stromal tumor 52 randomized #:# 52 prostate cancer HRPC 52 allogeneic bone marrow 52 Epratuzumab 52 vWD 52 hepatocellular cancer 52 dopaminergic therapy 52 taxane therapy 52 metastatic colon cancer 52 HCV genotype 1 52 NATRECOR R 52 trabectedin 52 differentiated thyroid 52 adverse cytogenetics 52 urothelial carcinoma 52 peg IFN 52 achieved CCyR 52 methotrexate therapy 52 Irinotecan 52 biochemical relapse 52 localized renal 52 DMARD therapy 52 telaprevir dosed 52 ribavirin therapy 52 progression TTP 52 juvenile idiopathic arthritis 52 MELAS 52 homozygous familial hypercholesterolemia 52 Peg IFN 52 eribulin mesylate 52 nonmetastatic prostate cancer 52 certolizumab 51 Telintra 51 SHPT 51 octreotide LAR 51 imatinib Gleevec ® 51 nonsmall cell lung cancer 51 medically inoperable 51 HGS ETR1 51 microalbuminuria 51 metastatic colorectal cancer 51 oral vancomycin 51 superficial bladder cancer 51 recurrent genital herpes 51 EGFR mutations 51 epithelial tumors 51 metastatic breast cancer 51 Malignant Melanoma 51 metastatic lung cancer 51 Mantle Cell Lymphoma 51 refractory chronic myeloid 51 chronic ITP 51 temozolomide 51 neuroendocrine tumors 51 myeloproliferative disorder 51 plus prednisone 51 metastatic cancer 51 pegylated interferon alfa 2a 51 histologically proven 51 FOLFOX6 51 AAT Deficiency 51 hematologic toxicity 51 myeloid metaplasia 51 decitabine 51 4mg/kg 51 unresectable liver cancer 51 HCV infected 51 solid tumors 51 tocilizumab 51 postherpetic neuralgia 51 HER2 positive 51 anthracycline taxane 51 achieved PASI 51 Idiopathic Pulmonary Fibrosis IPF 51 carcinoid syndrome 51 HNSCC 51 intermittent claudication 51 metastatic carcinoid 51 post herpetic neuralgia 51 Bortezomib 51 neovascular AMD 51 squamous histology 51 diabetic gastroparesis 51 advanced unresectable 51 Gleevec resistant 51 standard chemotherapy regimen 51 nilotinib 51 fluorouracil 51 diagnosed multiple myeloma 51 thyrotoxicosis 51 dose cohort 51 baminercept 51 sorafenib 51 adriamycin 51 decompensated heart failure 51 CIN3 51 hormone refractory prostate cancer 51 mycosis fungoides 51 DMARDs 51 Median survival 51 achieved sustained virological 51 distant metastasis 51 Anaplastic 51 depression TRD 51 malignant gliomas 51 underwent surgical resection 51 anthracyclines taxanes 51 Soft Tissue Sarcoma 51 mutated KRAS 51 papillary renal cell carcinoma 51 irinotecan chemotherapy 51 oblimersen 51 FOLFIRI alone 51 hematologic 51 refractory angina 51 alfa 2a 51 metastatic colorectal carcinoma 51 severe exacerbations 51 metastatic neuroendocrine tumors 51 anthracycline containing 51 opioid induced constipation OIC 51 rheumatoid arthritis RA 51 renal insufficiency 51 advanced epithelial ovarian 51 lupus erythematosus 51 carcinoma 51 adenoma 51 forodesine 51 AAT deficiency 51 Dacogen injection 51 neoadjuvant 51 Wegener granulomatosis 51 chronic HCV infection 51 TORISEL 51 refractory AML 51 Bronchiectasis 51 undetectable HCV RNA 51 alkylating agent 51 disease modifying antirheumatic 51 EBRT 51 pancreatic carcinoma 51 unstable angina UA 51 GIST 51 Myelodysplastic Syndrome 51 Surgical resection 51 colorectal liver metastases 51 cytotoxic chemotherapy 51 non squamous 51 ulcerative colitis UC 51 PAOD 51 Glioblastoma Multiforme GBM 51 relapsed AML 51 INCB# [002] 51 refractory Hodgkin lymphoma 51 Stage IIB 51 geographic atrophy 51 MGd 51 unresectable tumors 51 #mg/m# [002] 51 EXJADE 51 ulcerative colitis 51 metastatic relapsed 51 pulmonary hypertension PH 51 chronic eosinophilic leukemia 51 AA Amyloidosis 51 erythematosus 51 rheumatoid arthritis RA psoriatic 51 chronic HCV 51 Phase IIb trials 51 minimally symptomatic 51 nonmetastatic 51 bosutinib 51 Amrubicin 51 FluCAM 51 T2DM 51 dexamethasone Decadron 51 median PFS 51 histologies 51 VELCADE melphalan 51 LHON 51 HER2 negative 51 TELCYTA 51 doublet chemotherapy 51 SJIA 51 Leber congenital amaurosis LCA 51 diabetes mellitus DM 51 androgen deprivation 51 Relapsed 51 adjuvant therapy 51 metastatic pancreatic 51 VFEND 51 brain metastases 51 DMARD 51 recurrent malignant glioma 51 FOLPI regimen 51 Li Fraumeni Syndrome 51 primary hypercholesterolemia 51 oral Hycamtin 51 acute myeloid leukemia 51 prostate cancer mCRPC 51 infliximab therapy 51 tyrosine kinase inhibitors 51 soft tissue sarcomas 51 CRp 51 Chronic Lymphocytic Leukemia 51 gastric adenocarcinoma 51 tuberous sclerosis complex 51 advanced medullary thyroid 50 NYHA Class 50 taxane chemotherapy 50 neoadjuvant treatment 50 RRMS patients 50 arthritis PsA 50 progressive psoriatic arthritis 50 squamous cell 50 adenomatous polyps 50 RG# [001] 50 Xanafide 50 Rate ORR 50 valopicitabine 50 prior chemotherapy regimen 50 T#I [002] 50 peritoneal cancer 50 pegylated interferon 50 hematologic disorders 50 carcinoid 50 Cell Lymphoma 50 YERVOY 50 clinically localized prostate 50 opioid induced bowel dysfunction 50 Median PFS 50 NYHA Class III 50 huC# DM4 50 lymphocytic leukemia 50 erlotinib 50 castrate resistant 50 macular edema 50 Genasense ® 50 OncoVEX GM CSF 50 nodular BCC 50 imatinib mesylate Gleevec 50 primary immunodeficiency PI 50 cytoreduction 50 psoriatic arthritis PsA 50 actinic keratosis 50 neurological manifestations 50 ara C 50 Solid Tumours 50 refractory acute myeloid 50 sarcomatoid 50 peritoneal carcinomatosis 50 axitinib 50 myelodysplastic syndromes MDS 50 ruboxistaurin 50 fingolimod 50 Evoltra TM 50 Retreatment 50 pemetrexed 50 fluorouracil leucovorin 50 Rituximab 50 ZACTIMA 50 Sprycel dasatinib 50 Chronic Myeloid Leukemia 50 TNF inhibitors 50 axillary lymph node 50 erlotinib Tarceva 50 TTF Therapy 50 mcg albinterferon alfa 2b 50 Traficet EN 50 HCV RESPOND 2 50 PEGylated interferon beta 1a 50 tumor regression 50 Fludarabine 50 invasive aspergillosis 50 lung metastases 50 diagnosed glioblastoma multiforme 50 FOLFIRINOX 50 relapsed MM 50 glioblastoma multiforme GBM 50 post thrombotic syndrome 50 mitoxantrone chemotherapy 50 previously untreated follicular 50 #mg QD [002] 50 carboplatin 50 cell lung cancer 50 intravenous cyclophosphamide 50 opioid induced constipation 50 interferon alfa 50 cetuximab Erbitux ® 50 acute leukemia AML 50 imatinib 50 palliative radiotherapy 50 Mitomycin C 50 hypersensitivity reaction 50 sorafenib Nexavar 50 hormone deprivation 50 Flu Cy 50 active ankylosing spondylitis 50 Neovascular AMD 50 GnRH agonists 50 pomalidomide 50 octreotide 50 Hodgkin lymphoma HL 50 pCR 50 uveitis 50 low dose cytarabine 50 palifermin 50 systemic scleroderma 50 randomized #:#:# 50 squamous 50 imatinib Gleevec 50 Copegus ribavirin 50 administered subcutaneously 50 severe plaque psoriasis 50 stable angina pectoris 50 alemtuzumab treated 50 virus HCV protease inhibitor 50 post herpetic neuralgia PHN 50 BEACOPP 50 idiopathic thrombocytopenic purpura 50 myeloproliferative disorders 50 bronchiectasis 50 prostate carcinoma 50 partial onset seizures 50 essential thrombocythemia 50 MALT lymphoma 50 polyneuropathy CIDP 50 zalutumumab 50 colorectal carcinoma 50 bone metastases 50 posaconazole 50 chronic myelogenous leukemia CML 50 Waldenstrom macroglobulinemia 50 squamous cell cancer 50 CVP chemotherapy 50 phase IIb clinical 50 Diffuse Large B 50 relapsed leukemia 50 EGFR expressing mCRC 50 delayed onset CINV 50 PCa 50 carcinoid tumors 50 fulminant hepatitis 50 non Hodgkin Lymphoma 50 chemoresistant 50 basal cell carcinomas 50 proliferative retinopathy 50 urothelial bladder cancer 50 DFMO 50 plus ribavirin 50 palliation 50 Uricase PEG 50 Folfox 50 naïve HCV 50 paragangliomas 50 Severe Primary IGFD 50 null responders 50 DEB# 50 elacytarabine 50 acute GvHD 50 CML CP 50 operable breast cancer 50 Etanercept 50 visilizumab 50 levodopa therapy 49 Advanced Renal Cell 49 neutropenia dehydration dyspnea 49 cutaneous melanoma 49 pegylated alpha interferon 49 acute leukemias 49 biologic therapy 49 tanespimycin 49 carcinomas 49 docetaxel Taxotere ® 49 relapsed ovarian cancer 49 aHUS 49 cell carcinoma 49 peg interferon 49 medullary thyroid carcinoma 49 localized prostate cancer 49 serologically active systemic lupus 49 astrocytoma 49 resistant ovarian cancer 49 lamivudine refractory patients 49 aromatase inhibitor therapy 49 refractory myeloma 49 AA amyloidosis 49 Systemic Sclerosis 49 atypical Hemolytic Uremic Syndrome 49 5 fluorouracil leucovorin 49 superficial basal cell carcinoma 49 recurrent ovarian cancer 49 chemoembolization 49 basal cell carcinoma 49 follicular lymphoma FL 49 untreated chronic lymphocytic 49 immunosuppressed 49 metastatic colorectal 49 BRAF V#E mutation 49 mitoxantrone 49 anakinra 49 adjunctive placebo 49 Kit CD# positive 49 PKC# 49 hypomethylating agents 49 Adjuvant chemotherapy 49 Fludara ® 49 phase IIb study 49 diagnosed Ph + 49 placebo controlled clinical 49 BCG refractory 49 invasive candidiasis 49 Stage IIIb 49 liposomal doxorubicin 49 VICTRELIS 49 lymphadenectomy 49 febrile neutropenia 49 GLIADEL R Wafer 49 hypoparathyroidism 49 Acute Lymphocytic Leukemia 49 thromboembolic events 49 Free Survival PFS 49 hormone refractory 49 weekly subcutaneous injections 49 leiomyosarcoma 49 lymphoid malignancies 49 romiplostim 49 CRVO 49 metachronous 49 steroid refractory ulcerative 49 sulfasalazine 49 malignant pleural mesothelioma MPM 49 GnRH agonist 49 Alemtuzumab 49 dasatinib Sprycel 49 tolvaptan 49 Metastatic Prostate Cancer 49 metastatic CRPC 49 acute promyelocytic leukemia 49 malignant lymphoma 49 pertuzumab 49 BRAF V# mutation 49 pegylated interferon alfa 49 atypical hemolytic uremic syndrome 49 subcutaneous methylnaltrexone 49 resistant hormone refractory 49 failure NYHA 49 lobular carcinoma 49 advanced adenomas 49 mg/m2/day 49 daunorubicin 49 metastatic lesions 49 imatinib mesylate 49 SUTENT 49 Cloretazine 49 rilonacept 49 leukemia CML 49 lymph node involvement 49 receiving VELCADE 49 EGFR expressing 49 myelodysplastic myeloproliferative diseases 49 LHRH analogues 49 herpetic keratitis 49 receiving VICTRELIS 49 essential thrombocythemia ET 49 immunocompetent patients 49 familial adenomatous polyposis 49 liver resection 49 refractory prostate cancer 49 lymphoid blast 49 variceal bleeding 49 nasopharyngeal cancer 49 posterior uveitis 49 Myelodysplastic syndromes MDS 49 Chronic Lymphocytic Leukemia CLL 49 Ulcerative Colitis 49 homozygous FH 49 diagnosed GBM 49 keloid scarring 49 Chronic Sinusitis 49 pediatric Crohn disease 49 RRMS 49 Tasimelteon 49 lumbar spinal stenosis 49 mg m² 49 Gemcitabine 49 ankylosing spondylitis AS 49 adalimumab Humira 49 retinopathy 49 HRPC 49 Infusion reactions 49 papillary thyroid carcinoma 49 neovascular 49 stable angina 49 unstable angina 49 mcg kg 49 BRAF mutations 49 chronic granulomatous disease 49 nonresponders 49 TNF inhibitor 49 satraplatin Phase 49 Alocrest 49 invasive fungal infection 49 PRTX 49 BRIM2 49 eltrombopag 49 nutlin 3a 49 treatment naive genotype 49 amnestic mild cognitive impairment 49 terlipressin 49 Acute Coronary Syndromes ACS 49 infliximab 49 melphalan prednisone 49 BCG refractory carcinoma 49 advanced metastatic renal 49 ocular melanoma 49 transthyretin amyloidosis 49 Lenalidomide 49 Nexavar sorafenib 49 glioblastoma brain tumor 49 immunomodulatory therapy 49 abatacept 49 IMA# 49 cisplatin gemcitabine 49 TELINTRA 49 AML Leukemia 49 methotrexate 49 axillary dissection 49 Mitoxantrone 49 complement inhibitor eculizumab 49 oral candidiasis 49 plasma uric acid 49 cell carcinoma RCC 49 null responder HCV 49 mild renal insufficiency 49 HuMax EGFr 49 cell lymphoma DLBCL 49 inoperable pancreatic cancer 49 left ventricular dysfunction 49 chronic HCV genotype 49 pazopanib 49 nodular 49 occlusive disease 49 Natalizumab 49 MGUS 49 SCCHN 49 glioblastoma GBM 49 riociguat 49 Follicular lymphoma 49 haematologic 49 Navelbine ® 49 REMICADE ® 49 clodronate 49 gemcitabine 49 acute lymphoblastic 49 severe renal impairment 49 glioblastoma 49 chronically infected 49 peripheral sensory neuropathy 49 oral rivaroxaban 49 sorafenib Nexavar ® 49 neoplasm 49 Gorlin syndrome 49 cystic fibrosis bronchiectasis 49 PSADT 49 Cimzia TM 49 epirubicin 49 refractory metastatic 49 refractory CML 49 resected 49 IRX 2 49 TKI therapy 49 primary Restless Legs 49 XELOX 49 Idiopathic Pulmonary Fibrosis 49 mucosal healing 48 tiotropium 48 Wilms tumor 48 mitoxantrone plus 48 bortezomib 48 immune idiopathic thrombocytopenic 48 untreated multiple myeloma 48 graft dysfunction 48 refractory cutaneous T 48 radical nephrectomy 48 relapsed myeloma 48 nasopharyngeal carcinoma 48 bevacizumab Avastin ® 48 MPGN 48 oral mucositis 48 Metastatic 48 Allovectin 7 ® 48 micafungin 48 CBLC# 48 galiximab 48 bosentan 48 EVIZON 48 CTEPH 48 follicular non 48 nucleoside naive 48 AVASTIN 48 Amigal 48 adjuvant radiotherapy 48 gemcitabine Gemzar ® 48 CIMZIA TM certolizumab pegol 48 Acute Promyelocytic Leukemia 48 DIPG 48 anticancer therapy 48 biochemical recurrence 48 Tavocept 48 Acute Myeloid Leukemia 48 Paraplatin ® 48 low dose dexamethasone 48 cell lymphoma ALCL 48 Crohn disease CD 48 overt nephropathy 48 Pegasys plus Copegus 48 NOMID 48 systemic anaplastic large 48 Acute myeloid leukemia 48 Hycamtin 48 Capecitabine 48 Ozarelix 48 malignant neoplasm 48 FOLOTYN 48 adult chronic ITP 48 eribulin 48 hypereosinophilic syndrome 48 cardiogenic shock 48 uric acid lowering 48 bleomycin 48 peritumoral brain edema 48 prospectively defined 48 BRAF mutation 48 intestinal metaplasia 48 allogeneic stem cell 48 vulvar intraepithelial neoplasia 48 atherothrombotic events 48 voriconazole 48 KRAS status 48 Taxotere ® 48 talactoferrin 48 juvenile myoclonic epilepsy 48 alefacept 48 acetonide FA 48 Myelodysplastic syndromes 48 renal dysfunction 48 weekly intravenous infusions 48 intravenous bisphosphonates 48 Chronic Myeloid Leukemia CML 48 paclitaxel poliglumex